Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
2 Stocks to Buy Whether or Not a Recession Is Coming
02:37pm, Friday, 18'th Nov 2022 The Motley Fool
Both have outperformed the stock market this year.
Where Amgen Stands With Analysts
12:01pm, Friday, 18'th Nov 2022 Benzinga
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
2
2
0
Last 30D
0
0
0
The 3 Best Blue-Chip Stocks to Buy Now
03:48pm, Thursday, 17'th Nov 2022
When a bear market comes roaring, investors want to own the best blue-chip stocks. Believe it or not, there have been stocks recently hitting new 52-week and all-time highs.
Key Factors Driving Amgen's (AMGN) Outperformance This Year
02:54pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
The Zacks Analyst Blog Highlights Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works
11:39am, Thursday, 17'th Nov 2022 Zacks Investment Research
Novo Nordisk, Amgen, Automatic Data Processing, Equinor and Illinois Tool Works are included in this Analyst Blog.
Key Factors Driving Amgen's (AMGN) Outperformance This Year
11:17am, Thursday, 17'th Nov 2022
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Amgen's New Obesity Drug: Will Amgen Stock Skyrocket Through FDA Trials?
07:45am, Thursday, 17'th Nov 2022
So far, all signals point to a resounding yes. Amgen's obesity drug, AMG 133, completed a successful phase I trial, which helped lift the company's stock price.
Top Research Reports for Novo Nordisk, Amgen & ADP
09:26pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Amgen Inc. (AMGN) and Automatic Data Processing, Inc. (ADP).
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
02:40pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
11:18am, Wednesday, 16'th Nov 2022
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Pharmaceutical Stocks For Your November 2022 Watchlist
01:00pm, Tuesday, 15'th Nov 2022
3 pharmaceutical stocks to watch in the stock market right now.
The Dow is outperforming, which could be a sign that the latest stock-market rally will flame out
12:51pm, Tuesday, 15'th Nov 2022 MarketWatch
While investors seek shelter in more defensively oriented equity names, one market technician sees the Dow's growing margin of outperformance as a sign that the latest rebound in stocks might swiftly
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
11:20am, Tuesday, 15'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for IBB
Beat the Market Like Zacks: JPMorgan, Berkshire Hathaway, Amgen in Focus
11:55am, Monday, 14'th Nov 2022 Zacks Investment Research
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Amgen Inc. (AMGN) Presents at Credit Suisse 31st Annual Healthcare Conference Transcript
05:17am, Sunday, 13'th Nov 2022
Amgen Inc. (NASDAQ:AMGN ) Credit Suisse 31st Annual Healthcare Conference Call November 9, 2022 3:50 PM ET Company Participants Peter Griffith - EVP and CFO David Reese - EVP, Research and Development
